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Abstract The International Children’s Continence Society
(ICCS) has undertaken an enormous effort to standardize both
the terminology and management of various aspects of incon-
tinence in children, including enuresis, bladder overactivity,
dysfunctional voiding and psychological comorbidities. A
number of guidelines have been published to aid those in-
volved in the care of children with lower urinary tract symp-
toms. This review addresses a number of recommended diag-
nostic and therapeutic strategies, including urotherapy and
pharmacological treatment, with emphasis on a focused med-
ical history, information acquired from bladder diaries and
uroflow evaluations. The major role of urotherapy is
underlined with supportive pharmacotherapy, when indicated.
The article provides both a summary of ICCS guidelines and a
brief review of recently published papers related to the con-
temporary management of childhood incontinence, a health
issue still underestimated by both the child’s caregivers and
healthcare providers.
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ICCS International Children’s’ Continence Society
LUT Lower urinary tract
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Introduction
Overview of incontinence
An immense effort has been made by the International Chil-
dren’s Continence Society (ICCS) to standardize the terminol-
ogy of lower urinary tract (LUT) dysfunction in order to avoid
misunderstanding among all of the parties taking care of
children with LUT symptoms [1]. Detailed guidelines for the
diagnosis and treatment of the basic problems associated with
incontinence, as well as a list of clinically useful materials
(frequency/volume charts, bowel diaries) for the management
of children with this distressing condition, may be found on
their website (www.i-c-c-s.org).
According to the ICCS standardization document inconti-
nence may be intermittent (more common) or continuous
(implying an anatomical and/or neurological deficit). Intermit-
tent incontinence is applicable to children who are at least
5 years of age, and it is further classified as either night
(enuresis) or day wetting and as either primary or secondary
(occurring after a period of dryness of at least 6 months) [1].
The incidence of incontinence in childhood is high. A recent
study carried out in the UK reported a 15.5 % rate for enuresis
in 7.5-year-old children, which decreased with age but
remained at 0.5–1 % in adults [2]. Daytime incontinence has
been reported in 15 and 5 % of 4.5- and 9.5-year-old children,
respectively [3]. This distressing symptom is present in a
variety of underlying conditions, and the correct recognition
of the condition will determine the appropriate choice of
treatment. Due to the close anatomical and functional relation-
ship between the lower gastro-intestinal tract and the bladder,
an adequate assessment of both is crucial. Constipation needs
to be diagnosed and treated before and throughout inconti-
nence therapy [4]. The rate of comorbid behavioral and emo-
tional disorders in children with incontinence is high: epide-
miological studies have shown that 20–30 % of children with
nocturnal enuresis, 20–40 % with daytime urinary inconti-
nence and 30–50 % with fecal incontinence meet the criteria
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for psychiatric disorders. Consequently, physicians should
have a basic understanding of psychological principles and
apply the same care in the assessment of behavioral aspects as
is used to exclude the less frequently present organic causes of
incontinence [5].
Evaluation
History-taking is invaluable and although it is time-consuming,
the results of a well-focused medical history may directly lead
to a correct diagnosis without the need for additional tests and
examinations [1, 6, 7]. Based on medical history, patients can
be classified into the following basic subgroups:
monosymptomatic nocturnal enuresis (MNE), in whom only
nocturnal enuresis is present and non-monosymptomatic noc-
turnal enuresis (NMNE), in whom nocturnal enuresis is accom-
panied by other LUTsymptoms. This classification is clinically
relevant as these subgroups differ in terms of pathophysiology
and available therapy options. As such, it is important to
document all LUT symptoms, such as an increased/decreased
voiding frequency, daytime incontinence, urgency, hesitancy,
straining, a weak stream, intermittency, holding maneuvers, a
feeling of incomplete emptying, post-micturition dribble and
genital or LUT pain [7]. A full medical history should also
include drinking habits, bowel symptoms, any previous inter-
ventions and psychological aspects.
The second step in the structured diagnostic evaluation of a
child with incontinence is the physical examination. Special
attention should be paid to abdominal palpation in order to
exclude the presence of organomegaly, bladder distension or
fecal masses and to inspection of the genital and sacral regions
to exclude congenital malformations and cutaneous manifes-
tations of spinal dysraphism [6].
Frequency/volume charts and bladder diaries are tools
without which the reliable management of incontinence is
impossible. The information derived from these simple and
easily available charts is not only of diagnostic, but also of
therapeutic value for the child and their family. They will
allow the child’s caregivers to document maximal and average
voided volumes, voiding frequency, incontinence episodes,
bowel movements, fluid intake and urine production [1].
Behavioral comorbidities always need to be taken into
consideration. These can be screened for using a recently
published short, standardized questionnaire that has been spe-
cifically designed for children with enuresis [8]. If behavioral
comorbidities are recognized, further counseling is recom-
mended [5].
Further additional examinations to be considered include
urinalysis, ultrasonography and uroflow measurement. Uri-
nalysis will exclude urinary tract infection (UTI) as a possible
cause of the existing LUT symptoms. Ultrasonography may
be useful to recognize kidney and urinary tract abnormalities
and evaluate the bladder before and after micturition. It also
enables assessment of rectal distension caused by constipation
[9]. There is, however, scant evidence for the standard use of
ultrasound in every child with MNE. Non-invasive uroflow
with pelvic floor electromyography is helpful in identifying
dysfunctional voiding [1]. Further invasive procedures, such
as voiding cystourethrogram (VCUG), urodynamic investiga-
tion or spinal cord magnetic resonance imaging (MRI), should
be reserved for patients with suspected organic uropathies and
neurological problems, or those not responding to first-line
treatment [6].
Treatment
The basic therapeutic strategy for children with incontinence
is urotherapy. Urotherapy refers to nonpharmacological and
nonsurgical interventions used to treat LUT and bowel dys-
function. Standard urotherapy includes education on normal
LUT function, regular voiding habits and voiding posture,
life-style advice regarding fluid intake and prevention of
constipation and instruction on the use of bladder diaries or
frequency–volume charts. Urotherapeutic interventions en-
compass various methods of pelvic floor muscle (PFM) train-
ing, behavioral modification, neuromodulation and
catheterization.
Behavioral problems, if identified, need to be treated as
they affect both compliance and motivation of incontinence
therapy. Pharmacological treatment may or may not be added
to urotherapy as indicated.
Enuresis
Enuresis is the most common pathology related to the urinary
tract in children. According to ICCS recommendations enuresis
is defined as monosymptomatic (enuresis without any other
LUT s ymp t om s p r e s e n t d u r i n g t h e d a y ) o r
nonmonosymptomatic (if accompanied by daytime symptoms)
[1]. Two main pathophysiological causes of enuresis are recog-
nized: nocturnal polyuria, where decreased nocturnal vasopres-
sin levels have been demonstrated, or decreased bladder storage
during the night, which is frequently associated with overactiv-
ity of the bladder (OAB) [10, 11]. In both situations sleep
disturbancesmay play an important role. Although an increased
arousal threshold in children who do not wake to impulses from
the bladder is the most commonly implicated mechanism, more
complex pathways involving the sleep–awake cycle are being
recognized and evaluated [12–15].
Treatment
The general approach to the management of intermittent noc-
turnal incontinence is initial treatment of accompanying day-
time symptoms or of constipation, if present. Specific enuresis
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interventions include urotherapy, alarm treatment and
pharmacotherapy.
General lifestyle advice is given as part of standard
urotherapy. The child and their family should be informed
about the function of the urinary tract and the causes of
enuresis and thereafter be given advice on appropriate fluid
intake, regular voiding during the daytime and emptying the
bladder before going to bed. Special attention should be paid
to drinking habits. Regular fluid intake during the day and
minimization of fluid and solute intake 1–2 h before sleep is
encouraged in order to reduce increased nocturnal urine pro-
duction. A calendar of dry and wet nights should be kept for
self-monitoring and motivation. Alarm treatment or
desmopressin therapy should be discussed with the patient
and their family. Both methods are equivalent first-line treat-
ment options which can be proposed by the general practi-
tioner. The choice of initial treatment may be based on the
parents’ and child’s preference, the physician’s experience and
local resources. A proposed optimal treatment strategy is the
introduction of desmopressin in the presence of nocturnal
polyuria [urine production exceeding 130 % of the expected
bladder capacity (EBC) for a given age] and the choice of the
alarm for children with decreased maximal voided volumes.
Combined therapy with desmopressin and the alarm may be
effective in those children in whom both mechanisms are at
work or overlap [7, 16].
The alarm
Alarm therapy is based on the use of electronic devices which
sense moisture and trigger an alarm connected to the device.
The sensor can be placed in the child’s underwear or pad near
the perineum (a personal alarm) or in a mat on which the child
lies (a pad and bell alarm). Most alarms generate an acoustic
signal, although alarms with vibrations and light effects are
also available. Alarm therapy is curative in 60 % of children
through conditioning effects on arousal and/or increasing
bladder volume [17]. The minimal duration of therapy is
3 months, and it may be stopped after the child has achieved
at least 14 consecutive dry nights. Motivation and support
provided to the parents and child is crucial: the child needs to
learn to respond to the alarm (i.e. wake up), void in the toilet
and re-attach the alarm for the rest of the night. Recurrence of
enuresis may be observed, but re-introduction of this therapy
is often successful [7, 16].
Desmopressin
Desmopressin is an antidiuretic vasopressin analog which
leads to a decrease in urine production during the night.
Approximately 70 % of patients respond to desmopressin,
but a high recurrence rate is observed following cessation of
this therapy [7, 16]. The regular dosage is 0.2 mg of tablet
formulation, equivalent to 0.12 mg of melt tablets. The med-
ication should be taken at least 1 h before sleep to reach a
maximal effect, and fluid intake needs to be stopped 1 h before
administration. If complete response is not observed, the
dosage may be increased to 0.4 or 0.24 mg, respectively.
Patients with night-time polyuria and no bladder overactivity
are the best responders [18]. The advantage of this treatment
option is an immediate response, and it is therefore useful for
less motivated families. The treatment duration is 3–6 months,
with 1-month breaks to check if enuresis has resolved.
Desmopressin is a safe drug even with extended use, but the
caregivers and the child need to be warned that excessive fluid
intake just before or after drug administration may cause water
intoxication, hyponatremia and convulsions [7, 16].
Anticholinergic drugs
Although anticholinergic drugs are not the first-line treatment
option for nocturnal enuresis, they are used in combination
with other treatment modalities for resistant cases [19]. Sev-
eral studies have shown a significant improvement after the
addition of oxybutynin to desmopressin therapy [20]. Stan-
dard dosages of 5 mg of oxybutynin or 0.4 mg/kg propiverine
at bedtime have been used [20]. Suppression of the overactive
detrusor muscle may be beneficial in children with decreased
voided volumes and enuresis. Before antimuscarinic drugs are
introduced, constipation, post-void residual (PVR), low
voiding frequency and dysfunctional voiding need to be
excluded.
Centrally active medications
Several placebo controlled studies have demonstrated the
efficacy of imipramine, a tricyclic antidepressant, for the
treatment of nocturnal enuresis [21, 22]. Although the mech-
anism by which this is achieved is still unclear, it has been
postulated that this drug has antidiuretic properties and also
lowers the arousal threshold [23]. Imipramine is not available
in some countries due to its potential cardiotoxic effects.
Screening for long QT syndrome before starting treatment
has been proposed, although a normal electrocardiogram does
not exclude the possibility of developing arrhythmias. The
initial dosage of imipramine in children is 25–50 mg to be
taken at bedtime. A re-evaluation is performed after 1 month
of therapy; if full response has been reached, the drug is
tapered to the lowest effective dose. There should be a 2-
week break in therapy every third month to allow evaluation
of the resolution of enuresis. Imipramine should be used with
caution and looked upon as a tertiary treatment option to be
prescribed in specialist centers for the treatment of resistant
enuresis. Imipramine may be combined with either alarm
therapy or desmopressin [16].
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Day wetting
Lower urinary tract symptoms and day wetting occur in chil-
dren due to a variety of causes which include anOAB, voiding
postponement, an underactive urinary bladder (UUB), ob-
struction and dysfunctional voiding [1]. Other less likely
conditions are stress incontinence (occasionally associated
with obesity or chronic coughing), vesico- or urethro-vaginal
reflux and giggle incontinence.
Overactive bladder
Urgency is the main symptom of an OAB, which is termed
detrusor overactivity when confirmed by urodynamic investi-
gation. It is accompanied by increased voiding frequency,
decreased voided volumes and frequently by incontinence.
Children with OAB may demonstrate only urgency or urgen-
cy with incontinence of small volumes of urine, or involuntary
complete bladder emptying. Uninhibited detrusor contractions
lead to characteristic behavior patterns aimed at postponing
wetting, such as tiptoeing, forceful leg crossing or squatting
with the heel pressed into the perineum [1].
Treatment of this condition includes urotherapy with or
without pharmacotherapy. Both treatment options are comple-
mentary and their combined use seems to be more effective
[24]. Urotherapy involves the active management of bowel
dysfunction, implementation of age-appropriate regular fluid
intake and regular visits to the toilet. Charting facilitates
compliance and motivation. A timer watch can remind the
child of toilet visits and routine hydration. A personal wetting
alarm during the day may be helpful for carefully selected
children with concentration problems [24, 25].
Pharmacotherapy (oxybutynin, propiverin, tolterodin,
solifenacin)
Pharmacotherapy is introduced if the above interventions are
not sufficient to achieve continence. Antimuscarinic agents
which block acetylcholine receptors will inhibit the overactive
detrusor muscle. Unfortunately, most of the drugs currently
available are unselective and additionally interfere with the
muscarinic receptors localized outside the bladder, leading to
unwanted side-effects, of which the most common are dry
mouth, constipation and blurred vision, which in turn affects
compliance. These side-effects are caused by inhibition of M3
receptors present in the salivary glands, lower bowel and
ciliary smooth muscles [25]. Patients may also demonstrate
psychological or personality changes, as well as sympathetic
system activation with facial flushing, heat stroke, tachycar-
dia, drowsiness or headache. About 10 % of patients are
reported to discontinue therapy due to these side-effects
[26]. Special attention should be paid to the presence of
constipation; this needs to be actively treated before the
introduction of antimuscarinic therapy. PVR urine also needs
to be assessed before therapy and subsequently monitored
throughout therapy, as a residual can develop with time.
Treatment lasts 6–12 months, and the dosage should be ta-
pered slowly.
Oxybutinin Oxybutynin has been the most widely used
antimuscarinic drug. It is the only anticholinergic approved
by the U.S. Federal Drug Administration for use in children
with OAB. The recommended maximal dosage is 0.4 mg/kg
of bodyweight. Immediate release (IR), extended release (ER)
and transdermal forms of the drug are available. Oxybutinin is
an unselective antimuscarinic drug with a high side-effect
ratio, particularly for the IR formulation (dry mouth reported
in 17–97 % of subjects, constipation in 5–50 % and abnormal
vision in 3–24 %); a better tolerance was observed for the ER
and transdermal forms [27]. It has been suggested that the
side-effects of oxybutynin are fourfold more common in
children than in adults [28].
Propiverine Propiverine is an antimuscarinic with additional
calcium channel modulating properties which has been ac-
cepted for pediatric use in selected European countries. The
suggested pediatric dosage is 0.8 mg/kg/24 h. Studies present-
ed by Marschall-Kehrel et al. confirmed the efficacy of this
drug compared to placebo [29]. During a multicenter cohort
study the efficacy of propiverine and oxybutynin was similar,
but the former was associated with significantly fewer side-
effects, such as dizziness, nausea and hot flushes [30].
Tolterodine Tolterodine was introduced as a bladder selective
agent for OAB. Several studies in the adult population that
have compared tolterodine to oxybutynin reported a similar
efficacy but that the former had fewer side-effects [31]. The
available data in children are conflicting. Initial retrospective
studies in children seemed promising, confirming the superi-
ority of tolterodine over oxybutynin in terms of side-effects
[32], but subsequent randomized, double-blinded, clinical
trials failed to show any statistical difference between
tolterodine and placebo, or tolterodine and oxybutynin [33,
34]. Tolterodine has not been approved for use in children to
date and therefore has no recommended pediatric dosage.
Nevertheless, according to Hjälmås et al., the adult dosage
of 2 mg twice daily is comparable to 1 mg twice daily in
children aged 5–10 years [35].
Solifenacin Solifenacin is a novel, selective antimusarinic
with moderate selectivity for M3 over M2 receptors. It has
not been approved for pediatric use, but studies have shown a
good response and tolerance of this agent in children previ-
ously resistant to oxybutynin or tolterodine [36]. In a retro-
spective study of 138 children with OAB refractory to other
antimuscarinic agents, 5 mg of solifenacin was associated
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with an 85 % response rate (full and partial) and a 6.5 %
dropout due to side-effects [37]. A multicenter prospective
clinical trial is currently underway with a liquid suspension of
solifenacin, and a pediatric dosage and approval for pediatric
use may be established in the near future [38].
Botulin toxin
Botulin toxin A (BTA) treatment is a third-line option for
children with idiopathic detrusor overactivity which has been
refractory to noninvasive procedures such as urotherapy, PFM
training, neuromodulation and pharmacotherapy [39].
BTA is a neurotoxin produced by Clostridium botulinum
which causes bladder smooth muscle relaxation through inhi-
bition of acetylcholine release at the presynaptic cholinergic
junction [40]. BTA has been widely used off label in the
treatment of children with neurogenic detrusor overactivity.
Dosages between 5 and 12 U/kg body weight have been used
with good results [39–41]. During cystoscopy multiple (20–
50) injections of BTA into the detrusor muscle are made,
bypassing the trigone. Several recent publications have report-
ed the use of BTA for idiopathic detrusor overactivity in
children refractory to other forms of therapy [41]. McDowell
et al. presented a series of 57 patients with OAB resistant to
standard urotherapy who were treated with BTA and
antimuscarinics [42]. These authors observed success in
74.2 % of males and 54.5 % of females and partial success
in 20 % of males and 18.2 % of females [42]. The effect is
unfortunately not permanent, lasting only 6–9 months, and
repeated injections are necessary. At the present time there are
no ongoing studies evaluating the risk of fibrosis and alter-
ation of bladder compliance following BTA therapy in chil-
dren with idiopathic detrusor overactivity. Further treatment
concerns are urinary retention, cystitis and risk of UTI.
Neuromodulation
Neuromodulation is based on the principle that neural struc-
tures of the central nervous system may be activated through
the use of an electrical current which in turn may modulate the
innervation of the bladder. Several studies have shown that
treating children with OAB using electrical current at a fre-
quency between 10–25 Hz is a successful therapeutic ap-
proach. [43–46]. Neuromodulation may be an alternative
treatment to pharmacotherapy for OAB due to its efficacy
and lack of side-effects [47].
The treatment methods currently available include
parasacral transcutaneous electrical nerve stimulation (TENS;
parasacral), percutaneous tibial nerve stimulation/Stoller af-
ferent neuro-stimulation (PTNS/SANS) and implanted sacral
nerve stimulation (implanted SNS). The most commonly used
of these is home-based TENS with transcutaneous electrodes.
Percutaneous neuromodulation (PTNS) has also been shown
to be an effective method for the treatment of OAB: Hoebeke
et al. reported that 80 % of children improved following this
form of therapy [47]. Similar results have been reported for
parasacral TENS [48]. Nevertheless, further randomized trials
of larger patient groups are necessary to establish the role of
this method of therapy.
Voiding postponement
Some children with daytime wetting and urgency habitually
postpone micturation and defecation. This is frequently ob-
served during absorbing daytime activities, such as while
playing computer games or with contemporaries. The child
postpones bladder emptying as long as possible and conse-
quently wets his/her underwear due to an uninhibited reflex
from an overfilled bladder. This postponement may be asso-
ciated with constipation, as the child may also avoid poten-
tially painful defecation. Over time, constipation may lead to
fecal incontinence [1, 49]. Children demonstrating these
symptoms frequently suffer from psychological disturbances
[50].
The main aim of urotherapy is to correct the frequency of
micturition, ensure reasonable fluid intake and stop or reverse
bladder overdistension. Themonitoring of regular voiding and
drinking with the aid of frequency/volume charts or bladder
diaries and repeated uroflow and post- void residual evalua-
tions are necessary to assess the efficacy of ongoing treatment
[49].
Underactive urinary bladder
Children with decreased voiding frequency and increased
bladder volume exceeding 150 % expected bladder capacity
usually have UUB. This condition is related to a decreased
ability of the detrusor muscle to contract. The presence of an
UUB is indicated by an intermittent flow pattern and can be
confirmed by an urodynamic investigation. Children may
demonstrate infrequent micturition, an interrupted flow pat-
tern and the need to strain during voiding. An UUB may be
caused by neurologic (myelomeningocele, sacral agenesis,
cerebral palsy), anatomic (posterior urethral valve, bladder
outlet obstruction), functional (voiding postponement, dys-
functional voiding, constipation) or metabolic disorders (mi-
tochondrial diseases) [1, 49].
Muscarinic receptor agonists (bethanechol or carbachol) or
inhibitors of acetylcholine esterase (dist igmine,
pyridostigmine or neostigmine) have been used in the therapy
for UUB. Recent studies do not support the previous use of
parasympathomimetics for treating UUB [51].
The aim of urotherapy in the treatment of the underactive
bladder is to optimize bladder emptying and improve bladder
sensation. Education of the child and family consists of intro-
ducing regular voiding and drinking regimes, correcting
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voiding posture and PFM relaxation. Double voiding is a
useful technique when increased PVR are observed.
Clean intermittent catheterization may be necessary if UTI,
incontinence and incomplete emptying do not respond to
urotherapy. A standard regimen consists of five catheteriza-
tions daily (every 2–3 h). Hydrophilic-coated catheters seem
to be a better choice than uncoated ones, particularly in boys
in whom a painful insertion may cause treatment refusal [52].
In children with UUB, attention should be paid to overnight
bladder function in order to prevent further overdistension
[49]. An overnight catheter may be helpful when UUB coex-
ists with polyuria (early stages of renal insufficiency or dia-
betes insipidus).
Dysfunctional voiding
Dysfunctional voiding (DV) is defined and characterized by a
staccato uroflow pattern. This condition occurs due to incom-
plete relaxation of the PFM and sphincters during bladder
emptying, a mechanism that is also implicated in the incom-
plete emptying of the bowel which is frequently associated
with DV. DV can co-exist with bladder overactivity, wetting
and UTI. In response to a persisting functional obstruction to
flow, DV may lead to decompensation of the detrusor muscle
and bladder underactivity with resulting overflow inconti-
nence [1]. It may be helpful to discriminate whether the
internal or external sphincter is the cause of outflow obstruc-
tion. The external urethral sphincter is involved in the majority
of children, and for these children, PFM retraining is the first-
line treatment. The treatment for primary bladder neck dys-
function, when the internal sphincter does not relax, is differ-
ent [53].
Treatment
Urotherapy Urotherapy and muscle retraining will be suc-
cessful for the majority of patients with dysfunctional voiding.
The aim of urotherapy is to normalize bladder emptying and
storage by teaching relaxed voiding techniques. Fluid and
voiding regimes are also an essential part of the treatment.
The first step in achieving bladder emptying with a relaxed
pelvic floor is teaching the correct position and posture during
micturition. To urinate correctly, the child needs to have a
straight backwith the pelvis in a proper position. The feet need
to be supported, hips abducted, and buttocks well-supported.
Trousers and underpants should be pulled well down below
the knees, so they do not obstruct urine flow or limit voiding
position [49, 53–55].
Most children will learn relaxed voiding and bowel emp-
tying by being provided with simple instructions from an
urotherapist or nurse trained in muscle re-education. Some
children will require additional input. Biofeedback is a helpful
tool. This method has been used for treating a variety of
acquired behavior dysfunctions through the visualization of
physiological processes. Treatment of bladder disturbances
utilizes EMG tracing of PFM contraction and relaxation visu-
alized in the form of an animation tailored for children, or a
simple uroflow curve [56, 57]. Bower et al. reported a success
rate of 90 % for children with DV who followed a half-day
urotherapy program which included uroflow biofeedback and
instruction on the relaxation of PFM [58]. Animated biofeed-
back programswhich involve computer games are particularly
suitable for children and enable faster resolution of symptoms
when compared to non-animated methods [59]. Several stud-
ies have demonstrated a significant improvement in treatment
results with the addition of biofeedback to standard
urotherapy, but widespread use of this method is hampered
by the requirement of a dedicated staff and availability of
equipment [60].
Pharmacotherapy According to the ICCS statement there is
no approved pharmacological treatment for dysfunctional
voiding, but it may be considered when other forms of treat-
ment have failed [49]. The data on the use of alpha-blockers
are conflicting. Improvement in Qmax or PVR has been
reported, but therapy has usually been combined with bio-
feedback [61, 62]. Preliminary data have been published on
the use of tizanidine, a muscle relaxant, but more studies are
needed to assess its efficacy [63]. In primary bladder neck
obstruction, the alpha-receptors in the bladder neck have been
a target for pharmacological treatment. Alpha-blockers have
been used in order to decrease bladder neck resistance and
improve bladder emptying [54, 64, 65].
Promising data on the efficacy of botox injections into the
external sphincter have been reported in a small group of
children with DV resistant to other therapies [66, 67]. BTA
leads to temporary paralysis of the external sphincter and may
decrease functional bladder outlet obstruction. It has to be
stressed that this is an experimental treatment which may be
considered only if other forms of therapy fail.
Stress incontinence
Stress urinary incontinence (SUI) is the involuntary leakage
on effort, exertion, coughing or sneezing and is relatively rare
in neurologically intact children [1, 68, 69]. It may be ob-
served in adolescent girls with chronic cough, such as that
associated with cystic fibrosis or obesity. In children, wetting
during increased intra-abdominal pressure is more likely to be
due to masked OAB or an over-distended bladder. Stress
incontinence is recognized by an urodynamic investigation.
Involuntary leakage is observed during increasing intra-
abdominal pressure due to inadequate urethral closure
pressure.
Children with SUI should be advised about regular drink-
ing and voiding and in particular correct bowel habits. In
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adults, straining during defecation is highly associated with
this condition.While there is evidence for the efficacy of PFM
training for SUI in adults and young athletes in whom increas-
ing PFM strength has led to improvement of urinary inconti-
nence, reports on the treatment of children are lacking [70].
Vesico-vaginal reflux
Vesico-vaginal (or urethro-vaginal) reflux is a condition which
typically occurs in prepubertal girls. The urinary stream is
directed towards the vagina because of the position of the
urethral opening, entrapment of urine by the labia or poor
toilet posture and compression by the thighs. Wetting occurs
later, frequently during physical activities when urine,
entrapped in the vagina, leaks out. The hallmark of this
condition is post-void wetting. Vesico-vaginal reflux is a
possible cause of urine sample contamination and a possible
risk factor for UTI [71]. Girls suffering from vaginal reflux
should be instructed on how to spread the labia, abduct the
thighs and direct the urine stream forward by a non-flexed
lumbar spine during voiding. One option is to sit on the toilet
backwards because this position facilitates opening the labia
and pelvic posture [72]. Treatment of labial adhesions, meatal
anomalies and attention to diet (if overweight) may also be
helpful [73].
Giggle incontinence
Giggle incontinence is a rare but disturbing condition. The
pathogenesis is unclear, but it may be centrally mediated and
potentially is a hereditary disorder. It is characterized by
involuntary, complete bladder emptying during laughing with
otherwise normal bladder and bowel function [1]. It should
not be confused with dampness on laughing, which is a
manifestation of OAB.
Rapid and forceful recruitment of the PFM (known in adult
literature as “bracing”) can be helpful. Biofeedback has been
proposed as an alternative option [74]. Several studies have
reported the successful use of methylophenidate, a treatment
based on the postulated central system involvement of this
condition, but prolonged use of the drug may be necessary
[75, 76]. Dosages vary between 0.2 and 0.5 mg/kg daily with
an 8-h acting formulation and are administrated just before
school time, when the possibility of incontinence episodes is
highest [77].
Extraordinary daytime frequency
Children who suffer from extraordinary daytime frequency
syndrome present with an isolated symptom of sudden fre-
quent voiding of small volumes during the daytime without
any accompanying nocturia or wetting. Children may void at
least once hourly, and average voided volumes are <50 % of
EBC [1]. The condition is usually self-limiting. Age-
appropriate hydration with noncaffeine or nonacidic fluids is
a reasonable approach. Anticholinergic and anti-inflammatory
medications have been tried with varying success. Explana-
tion, re-assurance and psychological counseling are undertak-
en, if required.
Summary
Urinary incontinence is a common condition in children and
may be associated with constipation and psychological or
psychiatric disorders and less frequently with structural ab-
normalities of the urinary tract. The initial diagnostic approach
consists of a focused medical history and physical examina-
tion, a bladder diary or volume/frequency chart, urinalysis,
ultrasound of the urinary tract and screening for the presence
of behavioral problems. Further investigations will be neces-
sary in some children and may include uroflow and
urodynamic investigations, VCUG or MRI of the spinal cord.
Urotherapy is a first-line treatment for most conditions related
to incontinence, but pharmacological treatment may also be
helpful. Most children with enuresis, the most common con-
dition related to incontinence, can be treated by a primary care
physician or pediatrician. Other conditions may require the
expertise of a multidisciplinary pediatric team (nephrologist,
urologist, nurse, physiotherapist, gastroenterologist, psychol-
ogist, psychiatrist) for appropriate management. Although
urotherapy is a first-line treatment for most LUT dysfunctions,
standardization of this method is lacking. Further studies
are necessary to compare the efficacy of various
urotherapeutic interventions. Likewise, there is a need
for pediatric clinical trials of the newer pharmacological
agents.
Questions (answers are provided following
the reference lsit)
1. Children with urinary incontinence have high comorbid-
ity with:
a) Congenital malformations of urinary tract
b) Behavioral and psychiatric disorders
c) Obesity
d) Hypertension





e) Botulin toxin A (BTA)
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3. Urotherapy includes:
a) General lifestyle advice about proper fluid intake and
diet
b) Pelvic floor muscle retraining
c) Neuromodulation
d) All of the above
4. The second-line treatment for children with an underac-
tive bladder, significant post void residual and UTI who
do not respond to urotherapy is:
a) Oxybutynin
b) Clean intermittent catheterization
c) Desmopressin
d) Parasympathomimetics
5. Detailed guidelines on the diagnosis and treatment of
LUT dysfunction have been published by:
a) ICCS (International Children’s Continence Society)
b) ESPU (European Society for Pediatric Urology)
c) ESPN (European Society for Pediatric Nephrology)
d) AUA (American Urological Association)
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